Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
SURMOUNT-5 Trial Results This Phase 3b, open-label trial randomized 751 adults with obesity (but without diabetes) to receive either: Maximum tolerated dose of tirzepatide (10 mg or 15 mg) Maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) Key findings at 72 weeks: The trial concluded that tirzepatide was superior to semaglutide with respect to reduction in body weight and waist circumference at week 72
EGCG and GLP-1 receptor effects
Verify their cancellation policy before starting
Sterile water works for immediate use but degrades faster and offers no antimicrobial protection during storage
All compounds listed are supplied for laboratory research use only and are not intended for human or veterinary use
It acts on two hormone receptors: GLP and glucose-dependent insulinotropic polypeptide (GIP)
US$ 20.03
US$ 22.22
US$ 28.89
US$ 25.77
US$ 20.94
US$ 27.20
US$ 22.93
US$ 20.75
US$ 20.37
